Palonidipine (also known as TC 81) a calcium antagonist that was developed by Teijin for the treatment of hypertension and angina pectoris. Palonidipine was involved in phase II clinical trials in Japan. However, these studies were discontinued.

Pranidipine is the calcium channel blocker. Pranidipine did not affect the sensitivity of the contractile proteins to calcium. Pranidipine also did not alter cyclic GMP-induced relaxation in alpha-toxin-skinned vascular preparations. Pranidipine also prolonged glyceryl trinitrate-induced relaxation in the endothelium denuded rat aorta. Pranidipine enhances cyclic GMP-independent NO-induced relaxation of smooth muscle by a mechanism other than through NO-induced hyperpolarization. These effects were in direct contrast to amlodipine, another new 1,4-dihydropyridine calcium antagonist. Pranidipine increased blood velocity and probably blood flow in the optic nerve head, choroid, and retina of rabbits. Pranidipine was not detrimental to global cardiac function in animals with dilated cardiomyopathy. Pranidipine enhances relaxation produced by endothelium-derived relaxing factor in carotid artery. Pranidipine was investigated as pharmacological agent for the treatment of angina pectoris and hypertension.

Cronidipine (LF 2.0254) is a calcium channel blocker. LF 2.0254 inhibited in a time-dependent fashion K(+)- and Ca2(+)-induced contractions of rabbit aorta with respective IC50 of 2.7 nM and 1.7 nM. Cronidipine had a long-lasting antihypertensive action in spontaneously hypertensive rats and was able to decrease blood pressure and increase heart rate and plasma renin activity in hypertensive dogs.

Caldaret is intracardiac calcium (Ca2+) handling modulator whose cardioprotective actions are presumed to be due to inhibition of the NCX exchanger and increasing the uptake of Ca2+ via the sarcoplasmic reticulum (SR). Unfortunately, Caldaret failed to demonstrate efficacy in Phase II clinical trials as an adjunct to standard therapy with primary percutaneous coronary intervention patients diagnosed as having an acute myocardial infarction

Sornidipine, a nifedipine derivative, is a calcium channel blocker.

Brinazarone (SR33557) is a calcium channel blocker, that inhibits acid sphingomyelinase activity and enhances ricin-A chain immunotoxin activity. Brinazarone may act, much like perhexiline, by disturbing membrane lipid composition through their inhibitory action on lysosomal phospholipid hydrolases, such as acid sphingomyelinase, leading to modifications in intracellular routing and to subsequent degradation of ricin-A chain immunotoxins.

Diclofurime is a powerful coronary vasodilator, which lowers the resistance of large coronary arteries and decreases the O2 consumption of the myocardium. The activity of diclofurime is similar to digitalis: increase of cardiac flow, bradycardia, redistribution of the blood to peripheral area. These properties demonstrated in dogs have been confirmed in patients with cardiac diseases. Diclofurime is the antianginal agent. It might be effective in the control of cardiac arrhythmias since it exhibited both local anesthetic-like and calcium antagonistic properties. Diclofurime appears to be one of the most active and best tolerated drugs for long-term oral treatment of arterial hypertension.

Olradipine (also known as S 11568) is a L-type Ca(2+) channel antagonist. This drug was being developed in France for the treatment of heart failure, hypertension, and ischemic heart disorder. However, all these studies were discontinued.

Sagandipine was developed as a calcium channel blocker. Information about the current use of this compound is not available.

In the early stages of testing was shown that it is about 4 times more potent than gallopamil and 12 times more potent than verapamil in its effects on smooth muscle tone and labeled calcium uptake.